Efficacy and Safety of Proxalutamide in Severe or Critically Ill COVID-19 Patients: Study Protocol for an Exploratory Trial

June 2023 in “ BMC Pharmacology and Toxicology ”

Chunxue Bai, Minghe Ju, Hao Wang, Yichen Jia, Xiaodan Wang, Hao Fang, Jun Fan

proxalutamide androgen receptor antagonist

Studysummary This study is investigating the efficacy and safety of proxalutamide, an androgen receptor antagonist, in treating severe or critically ill patients with COVID-19, aiming to provide new insights into potential therapeutic options. Results are not reported yet.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on bmcpharmacoltoxicol.biomedcentral.com →

Discuss this study in the Community →

Research cited in this study

7 / 7 results

Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: An Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy with Proxalutamide

research Proxalutamide Improves Inflammatory, Immunologic, and Thrombogenic Markers in Mild-to-Moderate COVID-19 Males and Females: An Exploratory Analysis of a Randomized, Double-Blinded, Placebo-Controlled Trial Early Antiandrogen Therapy with Proxalutamide

5 citations , July 2021 in “medRxiv (Cold Spring Harbor Laboratory)”

This study found that proxalutamide improved immunologic, inflammatory, thrombotic, and oxygen markers in both female and male COVID-19 outpatients, which may support its association with lower hospitalization rates compared to standard care.

Proxalutamide Reduces Hospitalization Rate in Mild-to-Moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Trial

research Proxalutamide Reduces Hospitalization Rate in Mild-to-Moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Trial

5 citations , July 2021 in “medRxiv (Cold Spring Harbor Laboratory)”

This study found that proxalutamide treatment significantly reduced 30-day hospitalization rates in women with mild-to-moderate COVID-19 compared to placebo, with no safety issues identified.

Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

research Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

41 citations , February 2021 in “Cureus”

In this study, Proxalutamide significantly increased the rate of viral clearance and reduced clinical remission time in patients with mild to moderate COVID-19 compared to placebo.

research Alopecia and Grey Hair Are Associated with COVID-19 Severity

27 citations , October 2020 in “Experimental Dermatology”

This study found that both extensive grey hair and alopecia were independently associated with increased COVID-19 severity among survey respondents in Brazil.

research The Role of Androgens in COVID-19

40 citations , October 2020 in “Diabetes and Metabolic Syndrome: Clinical Research and Reviews”

This review discusses the potential role of androgens in increasing susceptibility to severe COVID-19 complications in men but presents no new clinical findings.

Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign

research Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign

32 citations , July 2020 in “Journal of The American Academy of Dermatology”

This study noted that among hospitalized COVID-19 patients, androgenetic alopecia was prevalent, and severe cases were associated with adverse outcomes such as respiratory failure, highlighting a possible link with androgen sensitivity.

research Male Balding Is a Major Risk Factor for Severe COVID-19

29 citations , July 2020 in “Journal of The American Academy of Dermatology”

In this study, researchers found that severe androgenic alopecia in hospitalized men was associated with a higher likelihood of testing positive for COVID-19.